Is this your business? Claim it to manage your IP and profile
xT CDx is an advanced genomic profiling solution used for comprehensive tumor and normal matched testing in oncology. With a focus on solid tumors, xT CDx leverages extensive gene coverage to aid in clinical decision-making. The system utilizes high-depth sequencing to provide actionable insights, aligning genomic findings with targeted therapy options. The platform is renowned for its substantial coverage of exons and is accredited for detecting a wide array of variants that contribute significantly to personalized medicine. As an in vitro diagnostic system, xT CDx is designed to serve as a companion diagnostic tool for oncologists, particularly in tailoring treatments that align with existing therapeutic guidelines. Its sophisticated analytical capabilities ensure that oncologists have the support they need to match patient profiles with clinical trials and approved treatments promptly. This facilitates a genomic-centric approach, integrating DNA sequencing insights into the broader clinical workflow. Incorporating both tumor and normal tissue comparisons, xT CDx is able to discern hereditary traits that might influence cancer treatment. This dual-approach testing enhances the diagnosis accuracy and optimizes treatment pathways, setting a new standard in oncology precision testing.
The xF+ Liquid Biopsy Panel by Tempus is specifically designed for the analysis of circulating tumor DNA (ctDNA) in solid tumor applications. By employing next-generation sequencing techniques, this panel offers an extensive coverage of regions that are pivotal in monitoring disease progression and treatment response. This non-invasive test is crucial for patients where traditional tissue biopsies may be impractical. The panel includes robust analytical capabilities that provide oncologists with valuable data on genetic mutations critical to treatment planning. With deep sequencing coverages and sophisticated genomic insights, xF+ is instrumental in navigating complex oncology cases, especially for its precision in pinpointing clinically relevant alterations that influence treatment choices. Featuring a unique methodology that emphasizes sensitivity and specificity, the xF+ Liquid Biopsy Panel plays an essential role in ongoing patient management. Its capability to analyze ctDNA provides critical insights into tumor dynamics over time, assisting healthcare professionals in evaluating therapy effectiveness and potential genomic mutations that could predict disease recurrence or progression.
Join the world's most advanced semiconductor IP marketplace!
It's free, and you'll get all the tools you need to evaluate IP, download trial versions and datasheets, and manage your evaluation workflow!
To evaluate IP you need to be logged into a buyer profile. Select a profile below, or create a new buyer profile for your company.
